Mutual Pharma Sanctioned In Sulindac Suit

Law360, New York (November 4, 2009, 5:14 PM EST) -- Mutual Pharmaceutical Co. Inc. will have to produce records related to potential side effects of sulindac and four other drugs for withholding a decade's worth of regulatory reports in a suit alleging its prescription anti-inflammatory drug caused a potentially fatal skin disease.

Judge Joseph N. Laplante of the U.S. District Court for the District of New Hampshire granted sanctions against Mutual on Monday, although he found the drugmaker had acted in good faith and stopped short of awarding all the relief plaintiffs Karen L. Bartlett and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.